Time-course changes in ectonucleotidase activities during experimental autoimmune encephalomyelitis.

Authors: Lavrnja, I  Bjelobaba, I  Stojiljkovic, M  Pekovic, S  Mostarica-Stojkovic, M  Stosic-Grujicic, S  Nedeljkovic, N 
Citation: Lavrnja I, etal., Neurochem Int. 2009 Sep;55(4):193-8. doi: 10.1016/j.neuint.2009.02.013. Epub 2009 Mar 5.
Pubmed: (View Article at PubMed) PMID:19524108
DOI: Full-text: DOI:10.1016/j.neuint.2009.02.013

The aim of the present study was to analyze the activities of extracellular purine metabolizing enzymes, CD39 (apyrase, EC 3.6.1.5) and CD73 (ecto-5' nucleotidase, EC 3.1.3.5) in experimental autoimmune encephalomyelitis (EAE). The levels of ATP, ADP and AMP hydrolysis were analyzed in the blood serum and in the rat spinal cord plasma membrane preparation 8, 15 and 25 days after induction of EAE. The animals were divided in three groups: control (saline), CFA (adjuvant-only) and EAE (CFA and homogenate of spinal cords). Eight days after immunization, ATP, ADP and AMP hydrolysis in the blood serum and spinal cord membrane preparations were unaffected in EAE compared to both, control and CFA group. In the peak of disease, ATP, ADP and AMP hydrolysis in EAE group showed significant decrease in the blood serum and prominent increase in the spinal cord membrane preparation compared to CFA and control group. At the end of illness, as judged by disappearance of clinical manifestation of EAE, ATP, ADP and AMP hydrolysis, although closer to CFA levels, were still significantly different in respect to the CFA group. Modulation of ATP, ADP and AMP hydrolysis suggests that they operate during EAE and might represent the basis of novel therapeutic strategies in immune-mediated diseases, such as MS.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 9685491
Created: 2015-01-13
Species: All species
Last Modified: 2015-01-13
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.